Scynexis (SCYX) Research & Development (2013 - 2026)
Scynexis (SCYX) posted Research & Development of $12.4 million for Q1 2026, up 171.75% on a QoQ basis from $4.5 million in Q4 2025, and up 140.25% year-over-year from $5.1 million in Q1 2025.
Scynexis (SCYX) Research & Development (2013 - 2026) Analysis & Trends
Scynexis' Research & Development history runs 14 years deep, the most recent figure standing at $12.4 million for Q1 2026.
- Quarterly Research & Development rose 140.25% year-over-year to $12.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.5 million (up 21.18% YoY) and the FY2025 annual result came in at $22.3 million, down 15.62% from the prior year.
- Research & Development was $12.4 million for Q1 2026 at Scynexis, up from $4.5 million in the prior quarter.
- Across five years, Research & Development topped out at $12.4 million in Q1 2026 and bottomed at $4.3 million in Q4 2024.
- A 5-year average of $7.0 million and a median of $6.8 million in 2023 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2024 — Research & Development sank 59.25% — and 2026, when it surged 140.25%.
- Scynexis' Research & Development stood at $7.8 million in 2022, then jumped by 34.87% to $10.6 million in 2023, then sank by 59.25% to $4.3 million in 2024, then increased by 5.35% to $4.5 million in 2025, then surged by 171.75% to $12.4 million in 2026.
- Business Quant data shows SCYX's Research & Development at $12.4 million in Q1 2026, $4.5 million in Q4 2025, and $5.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 696.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 180.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 7.37 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 138.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 248.60 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 296.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 97.00 Mn |
| 10 | Scynexis | 21.55 Mn | -15.20 Mn | - | 12.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.35 Mn |
| Dec 31, 2025 | 4.55 Mn |
| Sep 30, 2025 | 5.45 Mn |
| Jun 30, 2025 | 7.14 Mn |
| Mar 31, 2025 | 5.14 Mn |
| Dec 31, 2024 | 4.31 Mn |
| Sep 30, 2024 | 8.07 Mn |
| Jun 30, 2024 | 6.81 Mn |
| Mar 31, 2024 | 7.21 Mn |
| Dec 31, 2023 | 10.59 Mn |
| Sep 30, 2023 | 6.47 Mn |
| Jun 30, 2023 | 7.04 Mn |
| Mar 31, 2023 | 6.84 Mn |
| Dec 31, 2022 | 7.85 Mn |
| Sep 30, 2022 | 6.43 Mn |
| Jun 30, 2022 | 7.13 Mn |
| Mar 31, 2022 | 5.74 Mn |
| Dec 31, 2021 | 7.69 Mn |
| Sep 30, 2021 | 4.40 Mn |
| Jun 30, 2021 | 4.73 Mn |